Use of Monte Carlo simulations with a realistic rat phantom for examining the correlation between hematopoietic system response and red marrow absorbed dose in Brown Norway rats undergoing radionuclide therapy with 177Lu- and 90Y-BR96 mAbs

Medical Physics

Volumn 39, Issue 7, 2012, Pages 4434-4443

  Larsson, Erik ^a   Ljungberg, Michael ^a   Mårtensson, Linda ^a   Nilsson, Rune ^a   Tennvall, Jan ^a   Strand, Sven Erik ^a   Jönsson, Bo Anders ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

hematologic effect; internal dosimetry; Monte Carlo; radionuclide therapy; red marrow absorbed dose

Indexed keywords

BLOOD; BONE; CELLS; DOSIMETRY; MONOCLONAL ANTIBODIES; PHANTOMS; RADIOISOTOPES; RATS;

ABSORBED DOSE; ACTIVITY CONCENTRATION; HEMATOLOGIC EFFECT; HEMATOLOGICAL PARAMETERS; HEMATOPOIETIC SYSTEMS; MONTE CARLO CALCULATION; RADIONUCLIDE THERAPY; THERAPEUTIC EFFICACY;

MONTE CARLO METHODS;

ANIMALIA; RATTUS; RATTUS NORVEGICUS;

EID: 84864254477     PISSN: 00942405     EISSN: None     Source Type: Journal    
DOI: 10.1118/1.4730499     Document Type: Article

References (25)

1. 177Lu in rats: Establishment of a syngeneic tumor model to evaluate means to improve radioimmunotherapy., Clin. Cancer Res. 11, 7104-7108 (2005). 10.1158/1078-0432.CCR-1004-0004
2. T. M. Behr, M. Béhé, and G. Sgouros, Correlation of red marrow radiation dosimetry with myelotoxicity: Empirical factors influencing the radiation-induced myelotoxicity of radiolabeled antibodies, fragments and peptides in pre-clinical and clinical settings., Cancer Biother. Radiopharm. 17, 445-464 (2002). 10.1089/108497802760363231
3. 177Lu-labeled J591 antibodies specific for prostate-specific membrane antigen., J. Nucl. Med. 46, 850-858 (2005).
4. S. Lim, G. L. DeNardo, D. A. DeNardo, R. T. O'Donnell, A. Yuan, and S. J. DeNardo, Prediction of myelotoxicity using semi-quantitative marrow image scores., J. Nucl. Med. 38, 1749-1753 (1997).
5. S. M. Lim, G. L. DeNardo, D. A. DeNardo, S. Shen, A. Yuan, R. T. O'Donnell, and S. J. DeNardo, Prediction of myelotoxicity using radiation doses to marrow from body, blood and marrow sources., J. Nucl. Med. 38, 1374-1378 (1997).
6. C. Hindorf, M. Ljungberg, and S. E. Strand, Dosimetric model for mice and rats abstract, J. Nucl. Med. 44 (suppl), 150 (2003).
7. M. W. Konijnenberg, M. Bijster, E. P. Krenning, and M. De Jong, A stylized computational model of the rat for organ dosimetry in support of preclinical evaluations of peptide receptor radionuclide therapy with (90)Y, (111)In, or (177)Lu., J. Nucl. Med. 45, 1260-1269 (2004).
8. M. G. Stabin, T. E. Peterson, G. E. Holburn, and M. A. Emmons, Voxel-based mouse and rat models for internal dose calculations., J. Nucl. Med. 47, 655-659 (2006).
9. M. A. Keenan, M. G. Stabin, W. P. Segars, and M. J. Fernald, RADAR realistic animal model series for dose assessment., J. Nucl. Med. 51, 471-476 (2010). 10.2967/jnumed.109.070532
10. J. Chen, S.-E. Strand, J. Tennvall, L. Lindgren, C. Hindorf, and H.-O. Sjögren, Extracorporeal immunoadsorption compared to Avidin chase: Enhancement of tumor-to-normal tissue ratio for biotinylated rhenium-188-chimeric BR96., J. Nucl. Med. 38, 1934-1939 (1997).
11. K. Teramoto, K. Tsuji, T. Saito, T. Kuhara, K. Maejima, T. Ishihara, and M. Ishibashi, Changes in body weight and organ weight of Ishibashi (IS) rats with growth., Exp. Anim. 45, 317-323 (1996). 10.1538/expanim.45.317
12. Chapter 2 gross and elemental content of reference man., Annals of the ICRP/ICRP Publication 23, 273-234 (1975). 10.1016/s0074-2740(75)80022-5
13. J. S. Hendricks, MCNPX version 2.6.A, Vol. LA-UR-05-8225, Los Alamos National Laboratory, Los Alamos, NE, 2005.
14. M. G. Stabin and L. C. da Luz, Decay data for internal and external dose assessment., Health Phys. 83, 471-475 (2002). 10.1097/00004032-200210000-00004
15. ′″-tetraacetic acid and biotin before radiolabeling., Clin. Cancer Res. 11, 7171-7177 (2005). 10.1158/1078-0432.CCR-1004-0001
16. L. Mårtensson, R. Nilsson, T. Ohlsson, H. O. Sjögren, S. E. Strand, and J. Tennvall, Reduced myelotoxicity with sustained tumor concentration of radioimmunoconjugates in rats after extracorporeal depletion., J. Nucl. Med. 48, 269-276 (2007).
17. W. S. Snyder, M. R. Ford, G. G. Warner, and S. B. Watson, S, Absorbed Dose Per Unit Cumulated Activity for Selected Radionuclides and Organs (Society of Nuclear Medicine, 1975).
18. W. E. Bolch, K. F. Eckerman, G. Sgouros, and S. R. Thomas, MIRD pamphlet no. 21: A generalized schema for radiopharmaceutical dosimetry-standardization of nomenclature., J. Nucl. Med. 50, 477-484 (2009). 10.2967/jnumed.108.056036
19. J. A. Siegel, Bone marrow dosimetry and toxicity for radioimmunotherapy., Antibody Immunconj. Radiopharm. 3, 213-233 (1990).
20. G. Sgouros, Bone marrow dosimetry for radioimmunotherapy: Theoretical considerations., J. Nucl. Med. 34, 689-694 (1993).
21. D. Van Dyke, H. Anger, and M. Pollycove, The effect of erythropoietic stimulation on marrow distribution in man, rabbit and rat as shown by Fe59 and Fe52., Blood 24, 356-371 (1964).
22. H. B. Breitz, D. R. Fisher, and B. W. Wessels, Marrow toxicity and radiation absorbed dose estimates from rhenium-186-labeled monoclonal antibody., J. Nucl. Med. 39, 1746-1751 (1998).
23. J. A. Siegel, D. Yeldell, D. M. Goldenberg, M. G. Stabin, R. B. Sparks, R. M. Sharkey, A. Brenner, and R. D. Blumenthal, Red marrow radiation dose adjustment using plasma FLT3-L cytokine levels: Improved correlations between hematologic toxicity and bone marrow dose for radioimmunotherapy patients., J. Nucl. Med. 44, 67-76 (2003).
24. J. Elgqvist, P. Bernhardt, R. Hultborn, H. Jensen, B. Karlsson, S. Lindegren, E. Warnhammar, and L. Jacobsson, Myelotoxicity and RBE of 211At-conjugated monoclonal antibodies compared with 99mTc-conjugated monoclonal antibodies and 60Co irradiation in nude mice., J. Nucl. Med. 46, 464-471 (2005).
25. C. Hindorf, O. Linden, J. Tennvall, K. Wingårdh, and S. E. Strand, Time dependence of the activity concentration ratio of red marrow to blood and implications for red marrow dosimetry., Cancer 94, 1235-1239 (2002). 10.1002/cncr.10291